![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
-
Media ReleaseNovartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
-
Media ReleaseNovartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
-
Media ReleaseNovartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu
-
Media ReleaseNovartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben
-
Media ReleaseNovartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
-
Media ReleaseNovartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
-
Media ReleaseNovartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis
-
Media ReleaseNovartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
-
Media ReleaseNovartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
-
Media ReleaseNovartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
-
Media ReleaseNovartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 32
- › Next page